BAM
ZVRA icon

Blueshift Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Blueshift Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,702
Closed -$137K – 1278
2021
Q3 		$137K Buy
14,702
+1,549
+12% +$15.6K 0.01% 947
2021
Q2 		$169K Buy
+13,153
New +$141K 0.01% 856

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Blueshift Asset Management's ZVRA Position: Q4 2021 in Review

Blueshift Asset Management sold out of Zevra Therapeutics (ZVRA) in Q4 2021, closing a stake of 14,702 shares — an estimated $137K sold.

Blueshift Asset Management first reported a position in ZVRA in Q2 2021 and held it in 2 quarters. The position peaked at $169K in Q2 2021. 77 funds tracked by Wall St. Rank hold ZVRA as of Q4 2021.

  • Blueshift Asset Management reported no remaining Zevra Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 14,702 Zevra Therapeutics shares in Q4 2021, an estimated $137K.
  • Blueshift Asset Management first reported a position in Zevra Therapeutics in Q2 2021 and held it in 2 quarters.
  • Blueshift Asset Management's Zevra Therapeutics position peaked at $169K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.